Abeona Therapeutics (NASDAQ:ABEO) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Abeona Therapeutics (NASDAQ:ABEO) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.12), FiscalAI reports. The firm had revenue of $11.38 million during the quarter, compared to analysts’ expectations of $12.24 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN revenue rose 31% quarter over quarter to $11.4 million, with four revenue-generating treatments recognized in the second quarter. Abeona ended June with $146.8 million in cash, cash equivalents, and short-term investments.
• The commercial rollout expanded to seven activated qualified treatment centers, and 12 patients have been treated since launch, including five in Q2 and three more in Q3 to date. The company estimates about 40% of its addressable market now has in-state access to a treatment center.
• Launch execution remains operationally complex, with scheduling disruptions, two last-minute biopsy cancellations, one low-yield batch, and one out-of-specification batch. Both affected patients were treated, but Abeona will recognize no revenue for those two treatments and said the long-term rate of non-billable units remains uncertain.
• CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, making it one of only three of 15 traditional-pathway applicants to receive the designation. Although Medicare represents roughly 10% of the payer mix, Abeona expects NTAP to improve hospital economics and potentially support broader payer negotiations.
• Abeona reported a second-quarter net loss of $20.2 million, or $0.35 per share, compared with a $17.1 million loss in Q1. Gross margin was approximately 63%, though management expects margins could reach 85%–90% at steady-state volume as fixed manufacturing costs are spread across more treatments.

Abeona Therapeutics Stock Down 15.6%

ABEO traded down $1.16 during midday trading on Thursday, reaching $6.30. The company’s stock had a trading volume of 4,143,475 shares, compared to its average volume of 1,238,725. The firm has a market capitalization of $358.92 million, a price-to-earnings ratio of 6.50 and a beta of 1.35. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. Abeona Therapeutics has a 1 year low of $4.00 and a 1 year high of $7.65. The stock’s 50-day moving average is $6.29 and its 200-day moving average is $5.56.

Analyst Upgrades and Downgrades

ABEO has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, May 28th. Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings cut shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $19.00.

Insider Activity

In other news, Director Eric Crombez sold 26,143 shares of Abeona Therapeutics stock in a transaction on Friday, May 15th. The shares were sold at an average price of $5.53, for a total transaction of $144,570.79. Following the transaction, the director owned 37,313 shares in the company, valued at $206,340.89. This trade represents a 41.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Madhav Vasanthavada sold 12,606 shares of Abeona Therapeutics stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $6.96, for a total value of $87,737.76. Following the transaction, the insider directly owned 290,623 shares in the company, valued at approximately $2,022,736.08. The trade was a 4.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 307,221 shares of company stock valued at $1,854,494. 7.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc purchased a new position in shares of Abeona Therapeutics during the second quarter worth approximately $27,000. Russell Investments Group Ltd. purchased a new position in Abeona Therapeutics during the 3rd quarter worth $37,000. Truvestments Capital LLC raised its position in Abeona Therapeutics by 191.4% during the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 6,770 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in shares of Abeona Therapeutics in the 3rd quarter worth $64,000. Finally, Man Group plc bought a new position in shares of Abeona Therapeutics during the 2nd quarter worth $67,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.